特应性皮炎患儿角质层β-葡萄糖脑苷脂酶活性及葡萄糖基胆固醇水平升高且与局部细胞因子环境密切相关
该研究检测健康儿童与特应性皮炎(AD)患儿临床未受累皮肤角质层中β-葡萄糖脑苷脂酶(GBA)活性、葡萄糖基胆固醇(GlcChol)及含羟鞘氨醇碱基的葡糖神经酰胺(GlcCER[H])和神经酰胺(CER[H])水平,并分析其与疾病严重度、经皮水分丢失(TEWL)及局部细胞因子的关系。结果显示AD患儿基线GBA活性和GlcChol水平升高、局部外用糖皮质激素治疗6周后下降,CER[H]水平及CER[H]/GlcCER[H]比值升高,GBA活性和GlcChol与TEWL及多种细胞因子(尤其IL-1α和IL-18)相关,GlcChol与疾病严重度强相关。
要点
- AD患儿临床未受累皮肤角质层GBA活性和GlcChol水平较健康儿童升高,外用糖皮质激素治疗6周后下降。
- AD患儿角质层CER[H]水平及CER[H]/GlcCER[H]比值升高。
- GBA活性和GlcChol与TEWL及多种细胞因子(尤其IL-1α和IL-18)相关,GlcChol与疾病严重度强相关。
核心结论
- AD患儿角质层GBA活性和GlcChol水平升高,数据提示炎症在脂质加工紊乱中起重要作用。
- GBA活性或GlcChol可能作为监测AD治疗反应的生物标志物。
研究设计与样本
- 研究比较健康儿童与AD患儿临床未受累皮肤角质层,AD患儿接受局部外用糖皮质激素治疗6周前后对照。
- 检测角质层脂质标志物及先天免疫、Th1和Th2免疫相关细胞因子,以SCORAD评估严重度、TEWL评估皮肤屏障功能。
主要发现
- AD患儿基线GBA活性和GlcChol水平升高,治疗6周后下降。
- AD患儿角质层CER[H]水平及CER[H]与GlcCER[H]比值升高。
- GBA活性和GlcChol与TEWL及多种细胞因子相关,尤其与IL-1α和IL-18相关。
- GlcChol与疾病严重度强相关。
关键数值与推荐
- AD严重度采用Scoring Atopic Dermatitis(SCORAD)评估,皮肤屏障功能采用经皮水分丢失(TEWL)评估。
- 治疗为局部外用糖皮质激素,疗程6周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is characterized by immune dysregulations and an impaired skin barrier, including abnormalities in lipid organization. In the stratum corneum (SC), β-glucocerebrosidase (GBA) mediates transformation of glucosylceramide (GlcCER) into ceramide (CER) and cholesterol into glucosylcholesterol (GlcChol). Alteration in GBA activity might contribute to skin barrier defects in AD. OBJECTIVES: To investigate GBA activity in the SC of children with AD before and after topical corticosteroid therapy and to compare it with healthy controls; to determine SC levels of GlcCER- and CER-containing hydroxysphingosine base (GlcCER[H] and CER[H], respectively) and GlcChol; and to relate them to disease severity, skin barrier function and the local cytokine milieu. METHODS: Lipid markers and cytokines of innate, T helper 1 and T helper 2 immunity were determined in SC collected from healthy children and from clinically unaffected skin of children with AD, before and after 6 weeks of therapy with topical corticosteroids. AD severity was assessed by Scoring Atopic Dermatitis and skin barrier function by transepidermal water loss (TEWL). RESULTS: Baseline GBA activity and GlcChol levels were increased in children with AD but declined after therapy. CER[H] levels and the CER[H] to GlcCER[H] ratio were increased in AD. GBA activity and GlcChol correlated with TEWL and levels of multiple cytokines, especially interleukin-1α and interleukin-18. GlcChol was strongly associated with disease severity. CONCLUSIONS: We show increased GBA activity and levels of GlcChol in AD. Our data suggest an important role of inflammation in disturbed lipid processing. GBA activity or GlcChol might be useful biomarkers in the monitoring of therapeutic responses in AD. What is already known about this topic? Patients with atopic dermatitis (AD) have a reduced skin barrier, mainly caused by altered lipid organization. The mechanisms underlying these lipid anomalies are not fully understood but likely reflect both genetic abnormalities in AD skin and the local cutaneous inflammatory environment. What does this study add? We show increased activity of the ceramide-generating enzyme β-glucocerebrosidase in AD. Activity of this enzyme was correlated with the local cytokine milieu and declined after local corticosteroid therapy. We show that glucosylcholesterol levels in the stratum corneum are increased in AD. The function of glucosylcholesterol and the physiological consequences of increased levels are not clear yet; however, its levels were strongly correlated with skin barrier function: high transepidermal water loss strongly correlated with high levels of glucosylcholesterol. What is the translational message? Correction of cutaneous inflammation largely restores alterations in lipid metabolism in the stratum corneum of infants with AD.
引用
- Kezic S, McAleer MA, Jakasa I, et al. Children with atopic dermatitis show increased activity of β-glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to the local cytokine milieu. Br J Dermatol. 2022. PMID: 34993951. doi:10.1111/bjd.20979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。